Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Aeterna Zentaris

- PMLiVE

New diagnosis pathway has been launched to mark European Myeloma Day

The Myeloma Diagnosis Pathway aims to improve early diagnosis for patients

- PMLiVE

FDA halts third Merck myeloma trial after patient deaths

More patients died on Keytruda combination than those on other treatments

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Hopes ENDEAVOR trial results will give it an edge over Takeda's brand

Bristol-Myers Squibb (BMS) building

BMS gets two new cancer approvals in Europe

Empliciti, and Opdivo and Yervoy inhibitor combination get the green light

- PMLiVE

Amgen’s roll-out of myeloma drug Kyprolis reaches UK

Company hopes to gain NICE approval later this year

- PMLiVE

Amgen’s Kyprolis and Blincyto on track for European approval

Double CHMP recommendation backs the myeloma and leukaemia drugs

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

Novartis day

Novartis’ Farydak gets nod for myeloma in Europe

HDAC inhibitor offers new mechanism of action in fight against myeloma

- PMLiVE

Takeda files ‘oral Velcade’ for myeloma in US

Follow up could be the first pill approved for this rare cancer

- PMLiVE

Final NICE ‘no’ for Celgene’s Imnovid

England’s pricing watchdog says multiple myeloma drug is just too expensive for the NHS

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

- PMLiVE

Novartis gets OK for panobinostat in myeloma

First HDAC to receive positive FDA review

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links